RegulatoryAlerts Logo
RegulatoryAlerts
InsightsBlogPricingSign InStart Free Trial
Back to Home
MFDS (South Korea)
NOTICE
「의약품 등의 허가 등에 관한 수수료 규정」 일부고시개정(안)(공고 제2026-544호, 2026.11.6.)
Published: 11/6/2026Detected: 11/6/2026

Summary preview

Introduces a partial amendment draft to the MFDS fee regulation governing approvals for pharmaceuticals and related products.

Get the full analysis, free

Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.

Create free account
#MFDS
#fees
#drug approvals
#permit/approval
#public notice

Official Source Document
Source Verified

Access the original document directly from MFDS.

View Official Document

More from MFDS (South Korea)

  • 인체조직안전에 관한 규칙 일부개정령안 재입법예고 알림(공고 제2026-534호)11/6/2026
  • 첨단바이오의약품 안전 및 지원에 관한 규칙 일부개정령(안) 입법예고 알림(공고 제2026-533호)11/6/2026
  • 「나트륨·당류 저감 표시기준」 일부개정고시(안) 행정예고 알림(식품의약품안전처 공고 제2026-536호11/6/2026
  • 「임상시험용의약품 표시 등에 관한 규정」 제정고시(안) 행정예고(식품의약품안전처 공고 제2026-540호)11/5/2026
  • 「축산물의 검사명령에 관한 규정」 제정고시(안) 행정예고(공고 제2026-542호, 2026.11.5)11/5/2026

Get MFDS (South Korea) alerts in your inbox as they are published.

Free plan, 2-minute setup, no credit card required.

RegulatoryAlerts Logo
RegulatoryAlerts

Automated regulatory intelligence monitoring for pharmaceutical and biotech professionals. Track FDA, EMA, and Health Canada updates seamlessly.

Product

  • Insights
  • Updates by Therapeutic Area
  • FDA Updates
  • EMA Updates
  • Pricing
  • Features
  • Request Demo

Resources

  • Integration Guides
  • Regulatory Glossary
  • EMA Timeline
  • Best Practices
  • Therapeutic Areas

Company

  • About Us
  • Blog
  • Contact
  • Security
  • Privacy Policy
  • Terms of Service

    • © 2026 RegulatoryAlerts. All rights reserved.

    Not affiliated with the FDA, EMA, or Health Canada.